Introduction
Human cord blood contains a subset of stem cells, distinct from hematopoietic stem cells, which can differentiate into cells representative of all three germline layers. [1] [2] [3] [4] Although stem cells with multilineage potential are rare in unfractionated cord blood compared to hematopoietic stem cells, they can be expanded to give large numbers of cells for transplantation. 3 We follow Kogler et al. (2004) in using the term 'unrestricted somatic stem cells' (USSCs) to define these cells.
The identification of USSCs in cord blood opens up the possibility that either allogeneic or autologous stem cells could be used to treat diseases that affect any tissue in the body. A number of preclinical studies have demonstrated the therapeutic benefits of these multipotent cells in bone healing, in the reduction of graft versus host disease, and in the repair of myocardial infarcts. [5] [6] [7] In this study, we investigate the potential of USSCs to be genetically modified to enable normal expression of a gene of interest. Theoretically, USSCs isolated from patients diagnosed with genetic diseases could be gene corrected and returned to the patient from whom they were obtained. Cell therapy using gene-corrected autologous USSCs rather than immunologically matched allogeneic cells would avoid, rather than merely minimize, many of the problems associated with immunosuppression, while retaining a high potential for successful engraftment.
Genetically modified viruses remain the most popular vehicle of choice for gene transfer into mammalian cells, due to their high transduction efficiency. However, viral vectors generally accept relatively short DNA sequences and often use heterologous promoters to drive expression of human cDNA sequences. The removal of genes from their natural genomic context, together with random chromosomal integration, often leads to inappropriately regulated or variegated transgene expression that is particularly susceptible to transcriptional silencing and other positional effects. 8, 9 Designing artificial DNA constructs that mimic or reproduce natural physiological control mechanisms is difficult, especially when many of the complex mechanisms involved in the regulation of gene expression have yet to be fully elucidated. Conceptually, the simplest alternative is to deliver a native genomic construct of sufficient size to include all the short-and long-range cis-acting regulatory elements that are critical for the accurate control of gene expression.
Bacterial artificial chromosome (BAC) vectors can incorporate DNA inserts several hundred kilobases (kb) in size, large enough to include the full sequence of the majority of human genomic loci. To date, there have been numerous gene transfer studies that have used BACs containing intact genomic loci that show tissue-specific, physiologically regulated gene expression, and synthesis of the full spectrum of protein isoforms derived from a given locus. [10] [11] [12] [13] [14] [15] To our knowledge, however, the delivery of BACs to human stem cells capable of multilineage differentiation has never been reported.
Friedreich ataxia (FRDA) is a neurodegenerative, autosomal recessive disorder, caused by mutations in the FXN gene. The major transcript includes exons 1-5a that encompass 39 kb of genomic DNA. This is too large to be introduced into cells using commonly used viral vectors. In FRDA, the presence of a GAA trinucleotide repeat expansion in the first intron of the FXN gene causes reduced gene expression and lowers the amount of frataxin, a constitutively expressed protein which localizes to the mitochondria and has been implicated in the biosynthesis of iron-sulfur clusters. 16, 17 In tissues composed of long-lived cells such as the nervous system, this leads to increased oxidative stress in the mitochondria of patients, causing progressive loss of large neurons. The precise mechanisms causing the loss of neuron function over time are not understood. Development of a primary human cell line for use in investigating the effect of the entire FXN locus in neurons could provide insights into FRDA disease progression as well as the potential to introduce a functional FXN gene into stem cells from patients.
In this study, we report the delivery and integration into USSCs of a 195 kb BAC vector with an enhanced green fluorescent protein (EGFP) reporter gene fused to exon 5a of the complete frataxin (FXN) gene, the gene that when mutated causes the neurodegenerative disease FRDA. We show that transfection of USSCs with this genomic construct gives rise to clonal cell lines that stably express the FXN-EGFP transgene and retain multilineage differentiation capacity.
Results

Generation of USSC colonies following BAC transfection
Before electroporation into USSCs, BAC265::FXN-EGFP DNA was linearized within the BAC vector backbone using the BsiWI restriction endonuclease (Figure 1 ). The electroporation efficiency of large BACs is low; however, clones can be isolated and amplified following selection with antibiotics. From the one electroporation, six G418-resistant colonies were obtained. In this study, we describe the properties of two of these clones (termed clones 1 and 2). Initial attempts to clone the cells using limiting cell dilution were not successful. The successful use of cloning rings and antibiotic selection in this study may reflect the fact that extracellular matrix support, cell to cell contact and factors secreted by the cells are less compromised when cloning rings are used, compared to cells grown using limiting cell dilution.
PCR analysis confirmed the presence of DNA sequence specific to the EGFP and Neo R transgenes, as well as the presence of specific vector backbone sequences in the extreme 5 0 and 3 0 end of the linearized BAC in both clones (Figure 2a ). Southern blot analysis was performed to assess the presence and integrity of the BAC in both clones. Total genomic DNA from each clone was digested with the BamHI restriction endonuclease and hybridized with a Neo R -specific probe. The BamHIdigestion of BAC265::FXN-EGFP releases a 26 kb DNA fragment coding for exons 4-5a of the FXN gene as well as the EGFP/Neo R transgene cassette. Southern blot analysis of clones 1 and 2 revealed a single band that comigrated with the 26 kb band in the control lane containing BamHI-digested BAC DNA alone (Figure 2b ). Transgene gene copy number was also assessed by realtime PCR using the DDC T method. 18, 19 Following this analysis it was found that clone 1 is likely to contain two copies of the BAC transgene, whereas clone 2 is likely to contain three or four copies (Table 1) .
Fluorescent in situ hybridization (FISH) analysis, using BAC265::FXN-EGFP as a probe, was performed to assess whether genomic integration of the BAC had occurred in clones 1 and 2. For clone 1, a signal additional to the two endogenous FXN signals was observed, indicating that integration of the BAC into the nuclear genome had occurred, but not at the site of the existing FXN locus (Figure 2c ). In contrast, only two signals were detected for clone 2, both corresponding to the sites of the endogenous FXN loci. This phenomenon was consistently observed, suggesting that integration of the BAC transgene had occurred within or next to one of the endogenous FXN loci on chromosome 9. Additionally, for all of the cells analyzed in clone 2, the intensity of one of these signals was significantly greater when compared to the other. This is consistent with the real-time data and provides further evidence for multiple copies of the BAC transgene at the site of integration. The presence of multiple copies of a BAC transgene at a single integration site is a common observation and has been reported in a number of previous studies. 15, 20 
Transgene expression
The human FXN gene is a housekeeping gene expressed in all adult tissues at a low level, as well as during embryogenesis. 21 Thus, following delivery of the BAC265::FXN-EGFP into USSCs, the EGFP reporter gene, which is fused to the FXN gene, can be analyzed for expression both before and after differentiation. Expression of endogenous FXN was confirmed in untransfected USSCs using reverse transcription-PCR (RT-PCR; Figure 3a) . Subsequently, EGFP-and Neo Rspecific products were detected following RT-PCR analysis performed on the total RNA extracted from clones 1 and 2, confirming active transcription from the BAC265::FXN-EGFP transgene (Figure 3a) . Expression of FXN-EGFP mRNA was also confirmed by the presence of a 568 bp cDNA sequence across the FXN and EGFP junction, distinguishing this transcript from expression from the endogenous FXN gene. Expression of the frataxin-EGFP fusion protein was also detected in both clones following flow cytometric analysis (Figure 3b ). EGFP expression was sustained during the entire culturing period, with clone 1 consistently having a lower level of expression compared to clone 2. Using fluorescent microscopy, the frataxin-EGFP fusion protein was detected in the cytoplasm and had a punctated appearance in undifferentiated cells. Colocalization studies with antibodies for EGFP and the mitochondrial protein Cox-1 confirmed the mitochondrial localization of the fusion protein ( Figure 4 ). This was also observed following differentiation (Figure 4 ).
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Stably transfected USSCs retain differentiation capacity
To assess the multipotency of USSCs before and after electroporation, untransfected USSCs and transfected clones were differentiated into cells representative of the three germline layers using standard assays. Ectodermal differentiation capacity was determined by differentiating the cells in neural basal medium into cells that express neuronal-specific b-tubulin, as determined by antibody staining (Figure 5a ). Mesodermal differentiation capacity was confirmed by differentiating the cells in osteogenic-inducing medium into bone-like cells that have the capacity to mineralize, as determined by Alizarin Red S staining (Figure 5b In addition, the expression of EGFP after differentiation was also confirmed by microscopy in neuronal differentiated cells and by RT-PCR for epithelial differentiated cells (Figures 4 and 5c ). This EGFP expression was further validated using flow cytometry (data not shown). The quantification of EGFP expression after bone differentiation was not possible due to the significant calcification that was observed.
Discussion
There have now been a number of clinical and preclinical trials using gene-modified stem cells. Clinical trials using gene-modified hematopoietic stem cells have been undertaken to assess treatment of a number of Integration of a genomic locus into human stem cells F Zaibak et al hematological conditions. [22] [23] [24] [25] [26] [27] [28] Recent preclinical studies using in vitro cultured gene-modified mesenchymal stem cells have also shown promise. [29] [30] [31] [32] [33] However, in the majority of these studies, which use viral delivery of small vectors, random integration at multiple sites per cell and different sites between cells was documented, along with variegated expression and transcriptional silencing.
Although second generation vectors incorporating boundary and insulator elements will in some cases improve transgene expression and safety, a more ideal strategy would enable expression of the gene of interest from a genomic sequence that includes all of the native promoter and regulatory sequences. However, the transfection and integration of large genomic fragments is inefficient, and to date has only been seen with immortal cell lines and animal stem cell lines. 15, [34] [35] [36] [37] [38] [39] [40] [41] In this study, we demonstrate that human cord bloodderived USSCs, which have the capacity to proliferate and differentiate into a wide range of cell lineages, can be transfected with a 195 kb BAC vector containing a large genomic insert using a standard nonviral delivery technique. We show that after selection with antibiotics, Abbreviation: USSC, unrestricted somatic stem cell.
Integration of a genomic locus into human stem cells F Zaibak et al clonal cell lines can be obtained. Genomic integration was confirmed by the presence of BAC-specific DNA sequences in the clones, shown by PCR, real-time-PCR, Southern blot and FISH analyses. Southern blot analysis of the stably transfected clones revealed a single band of the expected size, indicating that 26 kb of the FXN-EGFP transgene had integrated into the genome intact and without any major rearrangements. Although this fragment contains only exons 4-5a of the FXN gene and the EGFP/Neo R transgenes, it is highly likely that the complete FXN gene, along with the upstream regulatory regions, was also present, as correct expression and mitochondrial localization of the frataxin-EGFP protein was observed in both clones. However, as a Southern blot to confirm the integrity of the entire BAC was not performed, we can only state definitively that the sequences at the extreme 5 0 and 3 0 ends of the BAC are present in clones 1 and 2 but cannot exclude the possibility of a rearrangement. Following FISH analysis of clone 1, in addition to the two signals representing the endogenous loci, a third signal on a different chromosome was observed, confirming the genomic integration of the BAC transgene. Conversely, only two signals were detected for clone 2, suggesting that integration of the BAC transgene had occurred either within or next to an endogenous FXN locus. Due to the large amount of sequence present in the BAC that is homologous to the endogenous gene, it is quite possible that a homologous recombination event may have taken place. This is in line with previous studies that have used BAC constructs for gene targeting in various cell types, including mouse embryonic stem cells. 42 However, the evaluation of additional clones as well as a more in-depth analysis at the site of integration is needed to confirm such an event and to determine the efficiency of this process in USSCs.
The expression of the frataxin-EGFP fusion protein was uniform within each clone, as evidenced by the single peak observed following flow cytometric analysis (Figure 3b ). This is in contrast to what is typically observed for a nonclonal population of cells transfected with small constructs where EGFP is driven off viral promoters, where large variations in transgene copy number, positional effects and transcriptional silencing Integration of a genomic locus into human stem cells F Zaibak et al Integration of a genomic locus into human stem cells F Zaibak et al result in multiple peaks that span over several logs. Although a significant variation in the level of EGFP expression was observed between the two clones, this is most likely due to differences in transgene copy number, as demonstrated by the real-time PCR data (Table 1) . However, it cannot be excluded that the site of transgene integration may also contribute to the differences in EGFP expression observed in clones 1 and 2. The USSCs that were used for the experiments we describe had been passaged six times before DNA delivery by electroporation. We estimate that this represents approximately 25 population doublings, as the cells were subcultured one in three at each passage. After electroporation, individual colonies were grown from a single cell and expanded to give 41 Â 10 7 cells. In all, cell cultures that were analyzed went through a total of 50 population doublings. Although this confirms the extraordinary proliferation capacity of these cells, we did observe a reduction in the proliferation rate at high population doublings. However, this did not appear to affect the functional differentiation capacity of the clones, as the cultures continued to maintain the differentiation properties observed in the parental USSCs.
The endodermal differentiation capacity of USSCs has been demonstrated in a number of ways including the formation of albumin-expressing hepatic cells in an in utero sheep model, and the expression of genes associated with endodermal-derived cell types. 3, [43] [44] [45] In this study, small airway growth medium (SAGM), an epithelial conditioned medium commonly used to differentiate stem cells into the endodermal-derived alveolar type II epithelial cells, was used to determine the capacity of the cells to undergo endodermal differentiation. [45] [46] [47] [48] Successful differentiation was confirmed by the upregulation of SPC, a gene specific to alveolar type II cells in the lung. SPC expression was not detected in the parental USSCs or clone 2 before differentiation, but clone 1 consistently showed a low basal level of expression. This may be due to heterogeneity in the starting cell population from which clone 1 was derived. Supporting the existence of different subpopulations Chang et al., 2006 recently isolated two distinct populations from cord blood that had different mesodermal differentiation capacities. 49 Alternatively, the higher basal level of SPC in clone 1 may reflect a low level of spontaneous differentiation. We regard it as unlikely that the expression is due to a positional effect of the integrated FXN BAC. Importantly, in each case, SPC gene expression was significantly upregulated after differentiation in SAGM.
The neuronal differentiation capacity of USSCs both in vitro and in vivo has been demonstrated by a number of independent laboratories. 3, 50, 51 In this study, the neuronal differentiation capacity of the clones was confirmed by the production of neuronal-specific b-tubulin after induction with neural basal medium. The clones exhibited a strong neuronal differentiation capacity with 490% of the cells staining positive for b-tubulin. Characteristic long projections including some evidence of branching was also observed.
The mesodermal differentiation capacity of USSCs is by far the most studied of all the three germline layers. USSC have been shown to enable reconstitution of femoral defects in mice 3, 5, 52 and to improve heart function after myocardial infarctions. 3, 7, 53, 54 In this study, mesodermal differentiation capacity of the clones was confirmed by the ability of the cells to mineralize after culturing in medium that induces stem cells down the osteogenic differentiation pathway. Distinct clusters of Alizarin Red S-stained cells were observed in both clones confirming successful mineralization. Taken together, these data indicate that gene-modified USSCs can be used in vitro to study gene expression from a BAC in both stem cells and different differentiated cell types. Validation of these gene-modified USSCs in animal models is also critical, as further evidence of differentiation capacity can be obtained and the safety of the cells can be determined. This is an essential prerequisite to the clinical application of gene-modified cells, particularly in light of the recent evidence of spontaneous transformation of some in vitro cultured stem cells. 55, 56 However, with improved culturing protocols, these safety concerns should be eliminated. In addition, the use of gene targeting strategies for BACs that have been successfully employed in mouse embryonic stem cells will enable the creation of gene-targeted stem cell lines, that would avoid all issues associated with random integration. The proof of principle for such studies has already been demonstrated in human embryonic stem cells using small DNA constructs. 57 Although a number of fundamental questions with respect to USSCs remain to be resolved, the successful demonstration in this study of the clonality of multipotent USSCs confirms the existence of a stem cell with multilineage differentiation capacity in cord blood. The successful delivery and expression of a functional BAC suggests that USSCs could potentially be used as hosts to express single or multiple genes of interest, opening up the possibility that cord blood-derived multilineage stem cells from patients may one day be corrected in vitro and returned to the patient, thus avoiding issues that arise with allogeneic transplantation. Such cells have the potential to be used therapeutically for many different tissues in the body.
Materials and methods
Isolation and culture of USSCs
Cord blood was collected with informed consent from mothers undergoing elective Cesarean section. The protocol was approved by the University of Melbourne and the Royal Women's Hospital Human Ethics Review Committees. Following delivery, the cord was clamped and blood was collected from the umbilical cord vein in bags containing 21 ml citrate phosphate dextrose (MacoPharma, Mouvaux, France). The USSC line was successfully generated as described by Kogler et al. 3 Briefly, the mononuclear cell fraction was separated by Ficoll gradient (density 1.077 g cm À3 ; GE Healthcare, Uppsala, Sweden) followed by ammonium chloride lysis of erythrocytes (0.17 M NH 4 Cl, 0.25 mM EDTA, 10 mM Tris pH7.4) and two washes with calcium-and magnesiumfree phosphate-buffered saline (PBS), pH 7.4. To initiate growth of the adherent USSC colonies, the mononuclear cell suspension was plated at 1 Â 10 7 cells per ml in initiation medium containing low-glucose Dulbecco's modified Eagle medium (Lonza, Walkersville, MD, USA) supplemented with 30% fetal calf serum (FCS; Hyclone, Logan, UT, USA), 10 À7 M dexamethasone (Sigma,
St Louis, MO, USA), 100 U ml À1 penicillin, 0.1 mg ml À1 streptomycin (Invitrogen, Chadsworth, CA, USA) and 2 mM ultra glutamine (Lonza). Cells were incubated at 37 1C in 5% CO 2 . Initiation medium was used to culture the cells until the first colony appeared. Expansion of the cells was performed using initiation medium without dexamethasone (proliferation medium). On reaching 80% confluency, the cells were subcultured using 0.25% trypsin/EDTA to remove adherent cells, and replated at 1:3 dilution in proliferation medium. Low passage cells were frozen at 1 Â 10 6 cells per ml in 10% dimethyl sulfoxide (Sigma) and 50% FCS (Hyclone).
To define the USSC population further, the proliferation capacity was confirmed by passaging the cells for 50 population doublings. The phenotype of the cells was confirmed using Medsaic immunomicroarray (Medsaic, Sydney, NSW, Australia) analysis of 149 antibodies; as expected the line was negative for CD34, CD24, CD31, CD45, MHCII and positive for CD44, CD71 and MHCI (see Supplementary data). The multilineage capacity of the cells was confirmed by differentiation into cells representative of the three germline layers.
USSC differentiation assays
To test for bone differentiation capacity, cells were cultured for 10 days in proliferation medium containing 10 À7 M dexamethasone, 10 mM glycerol-2-phosphate disodium salt (Sigma) and 50 mg ml À1 ascorbic acid (Sigma) as described by Jaiswal et al. 58 To confirm successful mineralization, cells were fixed for 10 min with 70% ice-cold ethanol at 4 1C and stained for 10 min with 1% Alizarin Red S (Sigma) in distilled water, pH 4.2, at room temperature. The cells were then washed five times in distilled water, layered in PBS (calcium and magnesium free) and images were captured using a using Leica DMIRB inverted microscope and AxioVision 4.2 software (Carl Zeiss AG, Oberkochen, Germany).
To demonstrate the neuronal differentiation capacity of the cells, the differentiation protocol described by Dottori et al. was adapted for USSCs. 59 Briefly, cells were plated on 10 mg ml À1 poly-D-lysine (Sigma), 10 mg ml À1 fibronectin (Becton Dickinson, Franklin Lakes, NJ, USA) coated glass coverslips and cultured in neural basal medium consisting of Neurobasal A with 2% B-27, 1% insulin-transferrin-selenium-A, 1% N2, 2 mM L-glutamine, 100 U ml À1 penicillin and 0.1 mg ml À1 streptomycin (all sourced from Invitrogen). Neural basal medium was supplemented with 20 ng ml À1 basic fibroblast growth factor (R&D Systems, Minneapolis, MN, USA) and 20 ng ml À1 epidermal growth factor (R&D Systems) before adding to the cells. Media was changed every 2 days, for a total culture period of 12 days.
Cells were maintained at 37 1C with 5% CO 2 in a humidified incubator. Differentiated cells were fixed in 4% paraformaldehyde for 10 min at 4 1C and immunostained overnight with 1 mg ml À1 of mouse IgG 1 antihuman b-tubulin III (Invitrogen), or 1 mg ml À1 of mouse IgG 1 isotype control (Dako, Glostrup, Denmark). Samples were then stained with 2 mg ml À1 goat anti-mouse Texas Red (Invitrogen). Before analysis, cells were counterstained with 1 mg ml À1 of 4,6-diamidino-2-phenylindole (DAPI) for 5 min, mounted in Vectashield (Vector Laboratories, Burlingame, CA, USA) and analyzed as described above.
To test for epithelial differentiation, cells were grown in SAGM (Lonza) as described by Berger et al. 60 Briefly, USSCs were seeded at 5 Â 10 5 cells per well in a six-well plate the day before the addition of SAGM. Cells were differentiated for 8 days and the medium was changed every 2 days. Successful differentiation was determined by RT-PCR for expression of the SPC gene. The human epithelial cell line CFBE41oÀ was used as a positive control for SPC expression.
Mitochondrial localization
The cells were grown on a slide and fixed in 4% paraformaldehyde for 10 min at 4 1C, then stored at À20 1C until needed. Slides were thawed and then heated to 95 1C for 15 min in antigen retrieval buffer (100 mM Tris, 5% Urea, pH9.5). Cells were permeablized in 0.1% TritonX-100 (Sigma) in PBS for 15 min at room temperature. Nonspecific antibody staining was blocked by incubating the cells in 10% goat serum for 1 h at room temperature. The cells were immunostained overnight with 2.5 mg ml À1 of mouse IgG 2b anti-human COXI antibody (Mitosciences, Oregon, USA), and/or 2.5 mg ml À1 of rabbit anti-EGFP (Invitrogen). Samples were stained with 2 mg ml À1 goat anti-mouse Alexa 594 (Invitrogen), and/or goat anti-rabbit Alexa 488 secondary antibodies. All washes were performed with 1% goat serum (Invitrogen) in PBS. Before analysis, cells were counterstained with 300 ng ml À1 of DAPI for 5 min, mounted in Vectashield (Vector Laboratories) and analyzed using an Olympus BX60 epifluorescence microscope. Images were captured using Cytovision software (Applied Imaging, San Jose, CA, USA).
BAC DNA
BAC265::FXN-EGFP, a derivative of the BAC clone RPCI-11 265B8, contains an in-frame fusion of the EGFP cDNA following the final codon of exon 5a of the FXN gene. 61 The genomic insert in BAC265::FXN-EGFP is 188.2 kb and contains exons 1-5b of the FXN locus (Figure 1) . The BAC was propagated in the Escherichia coli strain DH10B (Invitrogen) and purified using standard alkaline lysis procedures followed by CsCl-ethidium bromide density gradient centrifugation. The BAC was linearized with the BsiWI restriction endonuclease and subsequently purified by phenol/chloroform extraction.
Transfection
The day before transfection, passage six USSCs were seeded at 1 Â 10 6 cells per ml in stem cell proliferation medium. Immediately before transfection, cells were trypsinized, washed twice with OptiMEM (Invitrogen) and resuspended at a concentration of 5 Â 10 6 cells per ml. 0.5 ml of the cell suspension was mixed with B8 mg of the BsiWI-linearized BAC265::FXN-EGFP DNA and electroporated in a 0.4 cm cuvette using a Gene Pulser II (Bio-Rad, Hercules, CA, USA) with the following parameters: resistance, N; capacitance, 1000 mF; charge, 220 V. Cells were plated in a 140 mm petri dish in 20 ml of stem cell proliferation medium and incubated at 37 1C in 5% CO 2 . G418 was added to the culture media (200 mg ml À1 ) 2 days after transfection to select for stably transfected clonal cell lines over a period of 4-6 weeks. The medium containing fresh G418 was changed weekly during this period. Clones were individually isolated using cloning rings and expanded over a period of 2-3 months.
Flow cytometry
Flow cytometric analysis was performed using a LSRII flow cytometer (Becton Dickinson). Small cell debris and doublets were excluded based on FSC/SSC plots, after which 10 000 cells were collected and data analyzed using FACSDiva Software (Becton Dickinson).
Fluorescent in situ hybridization
Metaphase spreads were prepared according to standard procedures. Briefly, 2-4 Â 10 6 cells were cultured in the presence of 100 ng ml À1 colcemid (Invitrogen) for 3 h. Cells were then harvested and incubated in hypotonic solution (0.56% KCl) for 10 min. Cells were fixed in 3:1 methanol/acetic acid solution and left for at least 12 h at -20 1C before being dropped onto slides. BAC265::FXN-EGFP DNA was labeled with either Spectrum Red-dUTP or Spectrum Green-dUTP (Vysis, Downers Grove, IL, USA) using nick translation according to the manufacturer's protocol (Vysis). The labeled DNA probes, together with human Cot1 DNA, were alcohol precipitated and resuspended in hybridization buffer (50% formamide; 10% dextran sulfate; 2 Â sodium citrate buffer at a DNA concentration of 30 ng ml
À1
. The probes were denatured by heating to 72 1C for 8 min. Slides were denatured in 70% formamide, 30% 2 Â sodium citrate buffer at 70 1C for 2 min, dehydrated through an ethanol series, and 2 ml of probe added beneath a 10 mm coverslip. After hybridization overnight at 37 1C, the slides were washed in 1 Â sodium citrate buffer at 70 1C for 10 min. The slides were mounted in Vectashield containing DAPI (500 ng ml
) and examined using an Olympus BX60 epifluorescence microscope. Images were captured using Cytovision software (Applied Imaging).
Southern blot analysis
Total genomic DNA was isolated using the Nucleon BACC3 kit (GE Healthcare). Integration of the BAC265::FXN-EGFP transgene was examined by Southern blot analysis after digestion of the genomic DNA with the BamHI restriction endonuclease. The digested products were then separated by electrophoresis on a 0.8% agarose gel. The gel was subsequently incubated in depurination buffer (0.25 M HCl) for 10 min followed by 30 min incubation in denaturation buffer (1.5 M NaCl, 0.5 M NaOH). After rinsing in water, the gel was incubated in neutralization buffer (0.5 M Tris, 1.5 M NaCl) for a further 30 min. The DNA was then blotted onto a HybondN+ membrane (Amersham, Piscataway, NJ, USA) by capillary transfer in 20 Â sodium citrate buffer. A 431 bp probe specific for the neomycin resistance (Neo R ) gene was generated by PCR (Table 2 ) and labeled with 32 P using the Radprime DNA labeling system (Invitrogen) according to the manufacturer's recommendations. Hybridization was performed at 65 1C overnight in Church buffer (0.5 M Na 2 HPO 4 , 1 mM EDTA, 7% (w/v) SDS, 1% bovine serum albumin) at a probe concentration of 3 million c.p.m. ml
À1
.
PCR and RT-PCR
Total genomic DNA was extracted as detailed above. Total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen, Germantown, MD, USA) according the manufacturer's protocol and quantified using a NanoDrop 1000 spectrophotometer. cDNA was synthesized from 250 ng RNA using random hexamers from the Superscript III kit (Invitrogen), according to the manufacturer's protocol. Samples were amplified by PCR using the Taq PCR Core Kit (Qiagen). Briefly, 1 Â Buffer, 25 mM Table 2 .
Copy number determination
Genomic DNA was extracted using the Nucleon BACC3 kit (GE Healthcare). Samples were diluted to 12.5 ng ml À1 and 25 ng was used per reaction. To generate a standard ) was preformed to confirm the presence of a single amplicon. Samples were also run on a 2% agarose gel to confirm the size of the PCR product. The experiments were analyzed with auto baseline and manual threshold chosen from the exponential phase of the PCR amplification. The comparative C T (DDC T ) method was used to calculate copy number (2 ÀDDCT ) as previously described. 18, 19 Initial validation tests confirmed that the efficiency (E) of each primer pair were within 3% of each other (E ¼ (10 À1/slope À1) Â 100) and the absolute value of the slope of the DC T vs log input was o0.1 (0.089). The null hypothesis was that FXN and b-actin have the same copy number in USSCs. Therefore, a DDC T value of: 1.0 indicates no copies of the BAC (2 FXN:2 actin); 1.5 indicates one copy of the BAC (3 FXN:2 actin); 2.0, indicates two copies of the BAC (4 FXN:2 actin) and so on.
